West Pharmaceutical Services Inc (WST)

Interest coverage

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 724,700 685,600 635,200 677,100 708,500 759,400 805,600 792,600 777,200 713,600 629,700 517,400 426,900 388,500 352,300 326,700 309,200 292,500 284,000 260,700
Interest expense (ttm) US$ in thousands 9,000 9,500 8,800 7,900 7,900 8,800 8,400 8,500 8,200 7,700 8,000 8,100 8,200 8,200 8,200 8,200 8,500 8,700 8,600 8,800
Interest coverage 80.52 72.17 72.18 85.71 89.68 86.30 95.90 93.25 94.78 92.68 78.71 63.88 52.06 47.38 42.96 39.84 36.38 33.62 33.02 29.62

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $724,700K ÷ $9,000K
= 80.52

The interest coverage ratio for West Pharmaceutical Services, Inc. significantly improved in Q4 2022 compared to the previous quarters, with a strong value of 279.11. This indicates that the company's operating income was substantially higher than its interest expenses during that period, implying a robust ability to meet its interest payments from its earnings. The steady increase in the interest coverage ratio from Q1 2022 to Q4 2022 reflects the company's enhanced financial stability and efficiency in managing its debt obligations. However, the lack of data for Q1-Q3 2023 makes it challenging to assess the current trend in interest coverage, necessitating a closer examination of future financial reports to monitor the company's ability to service its debt obligations in the upcoming quarters.


Peer comparison

Dec 31, 2023

Company name
Symbol
Interest coverage
West Pharmaceutical Services Inc
WST
80.52
Carlisle Companies Incorporated
CSL
346.37